Research & Education

No strong association between lung cancer risk in women and reproductive history or hormone use

The Women’s Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for a role of hormone use in the incidence of lung cancer.

Physical activity benefits lung cancer patients and survivors.

Exercise and physical activity should be considered as therapeutic options for lung cancer as they have been shown to reduce symptoms, increase exercise tolerance, improve quality of life, and potentially reduce length of hospital stay and complications following surgery for lung cancer.

Early stage NSCLC patients with low tumor metabolic activity have longer survival.

Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer (NSCLC) is associated with increased overall survival and a longer time before tumor recurrence. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.

Early recall rates decline after second round of lung cancer screening.

The German Lung Cancer Screening Intervention Trial (LUSI) shows that the early repeat scan rate for suspicious findings decreased by more than 80% with the second and subsequent low-dose computed tomography (LDCT) screens, but emphasizes the need to have an organized screening program with the baseline scan available for comparison.

Concurrent chemoradiation treatment at high-volume facilities improves survival for non-small cell lung cancer patients.

Patients treated with definitive concurrent chemotherapy and radiation therapy (CCRT) for stage III non-small cell lung cancer (NSCLC) have longer overall survival when treated by highly experienced facilities, whether or not they are academic or community cancer centers.

Online education tool helps bridge gaps in therapeutic decision-making for advanced NSCLC.

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient’s molecular and clinical characteristics by providing feedback from an expert panel.

Pages